Gapping up
In reaction to strong earnings/guidance: MAGS +13.6%, FIVE +5.6%, RHT +5%, NVFY +5%, CMC +4.5%, DOVR +3.8%, CAG +3%, LTBR +2.8%, ACN +2.7%, FNV +2%, WGO +0.8%, INOV +0.7%, WOR +0.6%, RCI +0.6%, PVH +0.5%
M&A news: FSGI +1.3% (Atlantic Capital Bancshares announces merger agreement with First Security Group), GIS +0.9% (Bloomberg real M&A column discusses possibility of more M&A in the food space)
Select metals/mining stocks trading higher: AU +7%, HMY +4.8%, GFI +3.6%, AEM +3%, AG +3%, NEM +2.9%, GOLD +2.6%, GG +2.6%, SSRI +2.5%, GDX +2.3%, HL +2.2%, ABX +2%, FCX +1.5%
Select oil/gas related names showing strength: REXX +6%, SFY +5.3%, WTI +4.2%, PWE +4%, SDRL +3.4%, STO +3.2%, MRO +3.1%, SDRL +3%, GDP +2.9%, WLL +2.6%, RIG +2.4%, PBR +2.2%, CRR +2.2%, COP +2.1%, HAL +2%
Other news: CNAT +41.5% (announces top-line results from its Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease; trial met its primary endpoint), CRDC +16.7% (management committed to a corporate restructuring and layoff in which Cardica will be reducing its headcount by 15 people from 63 to 48 across all departments except research and development), VNR +3.9% (terminated, effective immediately, the Equity Distribution Agreement dated as of November 26, 2013 by and between the Company and Managers), VICL +3.1% (expanded its infectious disease portfolio with the addition of a novel antifungal, ASP2397, in-licensed from Astellas Pharma),TKMR +2.5% (presents preclinical results demonstrating super-additive effects on plasma triglyceride lowering by silencing of ApoC3 and ANGPTL3 genes), ROVI +2.1% (confirms that yesterday, the Northern District Court in Oakland, California held a hearing in its ongoing Netflix (NFLX) case), MDT +1.4% (highlights new data in JAMA Surgery demonstrating cost savings and reduced patient hospital stays following minimally invasive surgery), SLB +1.4% (resolved a previously disclosed investigation by the FOJ into past violations of U.S. sanctions ), MKC +0.9% (authorized new $600 mln share repurchase program)
Analyst comments: SBGL +2.9% (upgraded to Sector Outperform from Sector Perform at CIBC), AWAY +2.7% (initiated with an Outperform at Oppenheimer), PTX +2.4% (initiated with an Outperform at Oppenheimer), GPRO +2% (upgraded to Outperform from Neutral at Robert W. Baird), ALR +1.6% (upgraded to Neutral from Sell at Goldman
)
In reaction to strong earnings/guidance: MAGS +13.6%, FIVE +5.6%, RHT +5%, NVFY +5%, CMC +4.5%, DOVR +3.8%, CAG +3%, LTBR +2.8%, ACN +2.7%, FNV +2%, WGO +0.8%, INOV +0.7%, WOR +0.6%, RCI +0.6%, PVH +0.5%
M&A news: FSGI +1.3% (Atlantic Capital Bancshares announces merger agreement with First Security Group), GIS +0.9% (Bloomberg real M&A column discusses possibility of more M&A in the food space)
Select metals/mining stocks trading higher: AU +7%, HMY +4.8%, GFI +3.6%, AEM +3%, AG +3%, NEM +2.9%, GOLD +2.6%, GG +2.6%, SSRI +2.5%, GDX +2.3%, HL +2.2%, ABX +2%, FCX +1.5%
Select oil/gas related names showing strength: REXX +6%, SFY +5.3%, WTI +4.2%, PWE +4%, SDRL +3.4%, STO +3.2%, MRO +3.1%, SDRL +3%, GDP +2.9%, WLL +2.6%, RIG +2.4%, PBR +2.2%, CRR +2.2%, COP +2.1%, HAL +2%
Other news: CNAT +41.5% (announces top-line results from its Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease; trial met its primary endpoint), CRDC +16.7% (management committed to a corporate restructuring and layoff in which Cardica will be reducing its headcount by 15 people from 63 to 48 across all departments except research and development), VNR +3.9% (terminated, effective immediately, the Equity Distribution Agreement dated as of November 26, 2013 by and between the Company and Managers), VICL +3.1% (expanded its infectious disease portfolio with the addition of a novel antifungal, ASP2397, in-licensed from Astellas Pharma),TKMR +2.5% (presents preclinical results demonstrating super-additive effects on plasma triglyceride lowering by silencing of ApoC3 and ANGPTL3 genes), ROVI +2.1% (confirms that yesterday, the Northern District Court in Oakland, California held a hearing in its ongoing Netflix (NFLX) case), MDT +1.4% (highlights new data in JAMA Surgery demonstrating cost savings and reduced patient hospital stays following minimally invasive surgery), SLB +1.4% (resolved a previously disclosed investigation by the FOJ into past violations of U.S. sanctions ), MKC +0.9% (authorized new $600 mln share repurchase program)
Analyst comments: SBGL +2.9% (upgraded to Sector Outperform from Sector Perform at CIBC), AWAY +2.7% (initiated with an Outperform at Oppenheimer), PTX +2.4% (initiated with an Outperform at Oppenheimer), GPRO +2% (upgraded to Outperform from Neutral at Robert W. Baird), ALR +1.6% (upgraded to Neutral from Sell at Goldman
)